How to Reconstitute Thymosin Alpha-1: Dosing Math for mg, mL, and Units

What Is Thymosin Alpha-1 and Why Do Women Use It?

Thymosin Alpha-1 is a 28-amino-acid peptide naturally secreted by the thymus gland. It modulates T-cell maturation and dendritic cell activity, shifting the immune system toward more balanced Th1 and Treg activity. In clinical use, the branded form Zadaxin (SciClone Pharmaceuticals) has been studied in hepatitis B, hepatitis C, and as an adjunct in certain cancers.

For women specifically, TA-1 attracts interest across several conditions:

• Autoimmune thyroid disease. Hashimoto's thyroiditis affects women at roughly 7-to-1 over men, and its pathology is driven by dysregulated T-cell and NK-cell activity that TA-1 may help rebalance.
• PCOS-associated immune dysfunction. Women with polycystic ovary syndrome show elevated inflammatory cytokines and altered lymphocyte profiles. A 2020 study in the Journal of Ovarian Research noted that immune dysregulation is a co-driver of PCOS pathophysiology, not merely a side effect of androgen excess.
• Postpartum immune shifts. The postpartum period involves rapid immune remodeling. Postpartum thyroiditis, which affects 5-10% of women in the year after delivery, shares autoimmune mechanisms that TA-1 targets in thyroid-specific trials.
• Recurrent infection or chronic fatigue syndromes more prevalent in women than men.

The evidence base is genuinely thin for most of these women-specific uses. Most TA-1 trials enrolled predominantly male patients with viral hepatitis. Women reading this should understand that what is below applies extrapolated pharmacology, not direct female-cohort data. That gap is real, and your prescriber should acknowledge it.

The Reconstitution Math: A Step-by-Step Breakdown

Getting the concentration right is the most common source of dosing error. The calculation is straightforward once you fix the variables.

Step 1: Know Your Vial Size

Most U.S. Compounding pharmacies supply TA-1 in 1.5 mg lyophilized powder vials, which mirrors the Zadaxin commercial product. Some pharmacies also compound 3 mg or 6 mg vials. Confirm the printed label before you calculate anything.

Step 2: Choose a Target Concentration

You choose how much bacteriostatic water to add, which sets your final concentration.

| Bacteriostatic water added | Final concentration (1.5 mg vial) | Volume per 0.5 mg dose | |---|---|---| | 0.5 mL | 3.0 mg/mL | 0.17 mL (17 units on U-100) | | 1.0 mL | 1.5 mg/mL | 0.33 mL (33 units on U-100) | | 2.0 mL | 0.75 mg/mL | 0.67 mL (67 units on U-100) |

The 1 mL addition giving 1.5 mg/mL is the most commonly used concentration because the draw volumes are easy to read on a standard 1 mL insulin syringe and the math stays round.

Step 3: Calculate Your Specific Dose

The formula is:

Volume to draw (mL) = Desired dose (mg) ÷ Concentration (mg/mL)

Examples using a 1.5 mg/mL solution:

• 0.5 mg dose: 0.5 ÷ 1.5 = 0.33 mL = 33 units
• 1.0 mg dose: 1.0 ÷ 1.5 = 0.67 mL = 67 units
• 1.6 mg dose (Zadaxin standard): 1.6 ÷ 1.5 = 1.07 mL (requires a second draw or a 2 mL syringe; easier to use 2 mL diluent giving 0.75 mg/mL, then draw 2.13 mL, but a single 1.5 mg vial won't yield 1.6 mg unless dosed from a 3 mg vial)

The FDA-approved Zadaxin prescribing information references the 1.6 mg twice-weekly subcutaneous dosing established in hepatitis B registration trials. Compounded TA-1 used off-label at lower doses (0.5 mg to 1.0 mg) has no approved reference standard; those protocols come from clinical practice consensus, not a registered NDA.

Step 4: The IU Question

You may see TA-1 expressed in International Units (IU) on older literature or import documentation. The World Health Organization established that 1 mg of TA-1 = approximately 2,200 IU based on the first international standard established in 1991. The conversion:

• 0.5 mg = 1,100 IU
• 1.0 mg = 2,200 IU
• 1.6 mg = 3,520 IU

Compounded vials in the United States are labeled in milligrams (mg), not IU. If a source gives you a dose in IU, divide by 2,200 to convert to mg before drawing.

Bacteriostatic Water: Why It Matters and How to Use It

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative, which inhibits microbial growth and gives the reconstituted vial a usable multi-dose shelf life. USP <797> compounding standards classify a beyond-use date (BUD) for Category 1 compounded sterile preparations at 12 hours at room temperature or 24 hours refrigerated without assigned sterility testing, but most compounding pharmacies assign a longer BUD based on sterility testing under Category 2 conditions. In practice, reconstituted TA-1 with BWFI stored at 2-8°C is typically assigned a 21-day BUD by compounding pharmacies that conduct sterility and endotoxin testing.

Why Not Sterile Water?

Sterile water for injection contains no preservative. Once you pierce the septum with a needle, microbial contamination risk climbs with every subsequent draw. A 1.5 mg vial used over 2-3 weeks requires multiple needle insertions. Sterile water is appropriate only if you plan to use the entire vial in a single session, which is uncommon with TA-1 given its typical twice-weekly injection schedule.

What Not to Mix With

Do not reconstitute TA-1 with:

• Normal saline (0.9% NaCl): published stability data show peptide aggregation in saline versus aqueous buffered solutions for some thymosin fractions.
• Acetic acid solutions unless specifically instructed by your compounding pharmacy for a particular formulation.
• Any diluent that has been opened and stored outside sterile conditions.

Injection Technique for Women: Subcutaneous Sites and Practical Notes

TA-1 is given subcutaneously. Injection sites used in trials include the lateral abdomen, outer thigh, and upper arm. For women with higher subcutaneous fat distribution in the lateral thigh and abdomen (which is typical female-pattern fat distribution), these sites generally work well.

Insulin Syringe Selection

A U-100 insulin syringe with a 28-31 gauge, 5/16-inch (8 mm) needle is standard. The short needle is designed for subcutaneous tissue and avoids intramuscular injection, which matters in leaner women who may have less subcutaneous depth at the abdomen.

Reading the syringe:

• U-100 syringes are calibrated in units, where 100 units = 1.0 mL.
• Each 10 units = 0.10 mL.
• For a 33-unit draw (0.33 mL), pull the plunger to the "33" line.

Rotation and Site Care

Rotate injection sites with every dose. Lipohypertrophy from repeated subcutaneous injections at the same site affects peptide absorption. Women using TA-1 alongside other subcutaneous peptides (such as BPC-157 or thymosin beta-4) should map out site rotation across all agents to avoid tissue buildup.

Dosing Schedules Across Life Stages

Dosing in the published literature is primarily derived from Zadaxin hepatitis trials, which enrolled adults across a wide age range but did not stratify by reproductive status or menopausal stage. What follows reflects extrapolated clinical guidance:

Reproductive Years (Ages 18-40)

The most common compounded protocol in this age group uses 0.5 mg to 1.0 mg subcutaneously twice weekly for 4-12 weeks, then reassessed. Women in this group may use TA-1 for Hashimoto's disease or recurrent infections. No contraceptive interaction exists at the pharmacological level, but if TA-1 is prescribed alongside teratogenic co-medications, contraception becomes mandatory for those agents.

Perimenopause (Approximately Ages 40-52)

Perimenopause is characterized by fluctuating estrogen and progesterone with increasing immune dysregulation. Some practitioners note that women in perimenopause report worsening Hashimoto's flares coinciding with menstrual cycle irregularity. Thyroid autoantibodies, specifically anti-TPO and anti-thyroglobulin, fluctuate with estrogen. Estrogen receptors are expressed on T-regulatory cells, and declining estrogen reduces Treg activity, which is one mechanism TA-1 may partially compensate for. No clinical trial has tested TA-1 specifically in perimenopausal women with Hashimoto's; this is extrapolation.

Post-Menopause

Post-menopausal women show a shift toward more inflammatory immune profiles. A 2019 review in Frontiers in Immunology documented increased NK cell cytotoxicity and altered T-cell subset ratios after menopause, patterns that TA-1 influences in immunocompromised patients. No TA-1 trial has enrolled a post-menopausal cohort specifically.

Pregnancy, Lactation, and Contraception

TA-1 has no adequate controlled data in human pregnancy. It should not be used during pregnancy without explicit specialist oversight.

Pregnancy Category and Available Data

Thymosin Alpha-1 does not carry an FDA Pregnancy Category because it is not an FDA-approved drug in the United States in compounded form. The commercial product Zadaxin is approved in some Asian and Eastern European markets. The prescribing information for Zadaxin does not include human pregnancy safety data because pregnant women were excluded from registration trials.

Animal data: A 1993 study in International Journal of Immunopharmacology found no teratogenic effect in pregnant rats at doses up to 10 times the human equivalent, but rodent-to-human extrapolation for peptides with immune-modulating activity is unreliable. TA-1 acts on T-regulatory cell expansion and dendritic cell maturation, both of which are central to maintaining maternal-fetal immune tolerance. Theoretical concern exists that exogenous T-cell modulation could disrupt the Treg-mediated tolerance mechanisms essential to sustaining pregnancy, particularly in the first trimester.

Clinical instruction: Stop TA-1 at least 4 weeks before attempting conception unless you are under the active supervision of a reproductive endocrinologist or maternal-fetal medicine specialist who has reviewed your specific indication.

Lactation

No human lactation transfer data exists for TA-1. The peptide has a molecular weight of approximately 3,108 Da, which is large enough that passive diffusion into breast milk would be low, but not zero. Given the immune-modulating mechanism and absence of safety data, most clinicians advise pausing TA-1 during breastfeeding. The LactMed database at NIH does not have a Thymosin Alpha-1 entry as of the date of this review, reflecting the absence of published transfer data.

Contraception

TA-1 itself is not classified as a teratogen and does not mandate contraception on its own. If TA-1 is co-prescribed with a teratogenic agent (e.g., certain antifungals, retinoids, or methotrexate used off-label in autoimmune protocols), contraception requirements apply to those co-medications. Discuss the full medication list with your prescriber.

Who This Protocol Is Right For and Who Should Wait

More Likely to Benefit

• Women with confirmed Hashimoto's thyroiditis showing suboptimal T-regulatory cell activity on functional immunology testing, with a prescriber who has reviewed the thyroid autoimmunity literature.
• Women with documented recurrent sinopulmonary infections or chronic active Epstein-Barr virus who have failed standard care and have a physician or NP managing the protocol.
• Post-menopausal women with a specific immune indication where the evidence base, while thin, is the strongest available option in consultation with an internist or rheumatologist.

Should Wait or Avoid

• Pregnant women or those actively trying to conceive without a reproductive specialist co-managing care.
• Women breastfeeding exclusively.
• Women with active autoimmune flare where escalating immune activity is a risk; TA-1 increases T-cell activity and could theoretically worsen certain flares if Th1/Th17 imbalance is already the driver.
• Women with a known malignancy, because T-cell modulation in the setting of cancer therapy requires oncology coordination.
• Women sourcing TA-1 from grey-market suppliers without USP <797>-compliant compounding. Peptide purity and sterility cannot be assumed outside a licensed compounding pharmacy.

Stability, Storage, and the 21-Day Rule

Once you add bacteriostatic water to the lyophilized powder, a clock starts. The peptide bonds are intact but the molecule is now in solution and subject to hydrolysis, aggregation, and microbial risk.

Key storage rules:

• Reconstituted vial: Refrigerate at 2-8°C immediately after reconstitution. Do not freeze.
• Beyond-use date: Discard after the date assigned by your compounding pharmacy. If no date is assigned, USP <797> Category 2 guidance supports a maximum of 45 days refrigerated for sterility-tested sterile preparations, but most compounding pharmacies set a more conservative 21 days.
• Lyophilized powder before reconstitution: Store at 2-8°C or as labeled. Some pharmacies ship with dry ice and specify room-temperature stability for up to 72 hours during transit.
• Inspect before use: The reconstituted solution should be clear and colorless. Any particulate matter, cloudiness, or color change means discard, no exceptions.

A 2003 peptide stability review in the Journal of Pharmaceutical Sciences found that thymosin peptides in aqueous solution showed measurable degradation within 30 days at room temperature, reinforcing refrigerated storage as non-negotiable.

Evidence Gaps Women Should Know About

The TA-1 trial record is real but narrow. The largest studies are:

• Thymosin Alpha-1 in hepatitis B (ZADAXIS registration trials, 1995-2000): Enrolled approximately 400 patients predominantly male across Asian trial sites. Demonstrated improved HBeAg seroconversion at 1.6 mg subcutaneously twice weekly for 26 weeks. Women's subgroup data was not published separately.
• A 2019 meta-analysis of TA-1 in sepsis published in Critical Care Medicine found reduced 28-day mortality in severe sepsis patients given TA-1 versus placebo, but again without sex-stratified reporting.
• No randomized controlled trial has enrolled women with Hashimoto's thyroiditis, PCOS, or postpartum thyroiditis as a primary population for TA-1. What is recommended in those contexts is clinical extrapolation from immunology mechanism data, not direct female-cohort evidence.

Women deserve to know this. The honest answer is: the reconstitution math is solid, the pharmacology is plausible for several women's immune conditions, and the direct female-specific trial data does not yet exist.

Quick Reference: Reconstitution Cheat Sheet

| Vial size | Diluent added | Concentration | 0.5 mg dose | 1.0 mg dose | 1.6 mg dose | |---|---|---|---|---|---| | 1.5 mg | 0.5 mL BWFI | 3.0 mg/mL | 17 units | 33 units | 53 units | | 1.5 mg | 1.0 mL BWFI | 1.5 mg/mL | 33 units | 67 units | 107 units* | | 3.0 mg | 1.0 mL BWFI | 3.0 mg/mL | 17 units | 33 units | 53 units | | 3.0 mg | 2.0 mL BWFI | 1.5 mg/mL | 33 units | 67 units | 107 units* |

*107 units exceeds a standard 1 mL insulin syringe. Use a 2 mL syringe or a 3 mg vial with 1 mL diluent to keep the draw under 60 units at 53 units per 1.6 mg dose.